Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;11(10):1599-617.
doi: 10.1517/17425255.2015.1068757. Epub 2015 Jul 14.

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19

Yao Yang  1 , Joshua P Lewis  2 , Jean-Sébastien Hulot  3   4 , Stuart A Scott  1
Affiliations
Review

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19

Yao Yang et al. Expert Opin Drug Metab Toxicol. 2015.

Abstract

Introduction: Aspirin, clopidogrel, prasugrel and ticagrelor are antiplatelet agents for the prevention of ischemic events in patients with acute coronary syndromes (ACS), percutaneous coronary intervention (PCI) and other indications. Variability in response is observed to different degrees with these agents, which can translate to increased risks for adverse cardiovascular events. As such, potential pharmacogenetic determinants of antiplatelet pharmacokinetics, pharmacodynamics and clinical outcomes have been actively studied.

Areas covered: This article provides an overview of the available antiplatelet pharmacogenetics literature. Evidence supporting the significance of candidate genes and their potential influence on antiplatelet response and clinical outcomes are summarized and evaluated. Additional focus is directed at CYP2C19 and clopidogrel response, including the availability of clinical testing and genotype-directed antiplatelet therapy.

Expert opinion: The reported aspirin response candidate genes have not been adequately replicated and few candidate genes have thus far been implicated in prasugrel or ticagrelor response. However, abundant data support the clinical validity of CYP2C19 and clopidogrel response variability among ACS/PCI patients. Although limited prospective trial data are available to support the utility of routine CYP2C19 testing, the increased risks for reduced clopidogrel efficacy among ACS/PCI patients that carry CYP2C19 loss-of-function alleles should be considered when genotype results are available.

Keywords: CYP2C19; antiplatelet agents; aspirin; candidate genes; clopidogrel; pharmacogenetics; pharmacogenomics; prasugrel; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

Financial and competing interests disclosure

JP Lewis receives support from NIH for antiplatelet pharmacogenomics research. J-S Hulot has received research grant support from Biotronik, and consulting fees from Daiichi Sankyo. SA Scott receives support from NIH for antiplatelet pharmacogenomics research and is an Associate Director of a clinical laboratory that performs CYP2C19 testing. This research was supported in part by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH), through grants K23 GM102678 (J.P.L.) and K23 GM104401 (S.A.S.). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed

Figures

Figure 1
Figure 1
Metabolic pathway of P2Y12-receptor inhibitors. CYP: cytochrome P450; GP: glycoprotein; hCE: human carboxylesterase; MDR1: multidrug resistance protein 1. Reprinted by permission from Macmillan Publishers Ltd: [199] © 2014.
Figure 2
Figure 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) algorithm for suggested clinical actions based on CYP2C19 genotype when considering clopidogrel treatment for ACS/PCI patients. ACS: acute coronary syndromes; PCI: percutaneous coronary intervention; UM: ultrarapid metabolizer; EM: extensive metabolizer; IM: intermediate metabolizer; PM: poor metabolizer. 1 Other possible CYP2C19 genotypes with rare loss-of-function alleles exist beyond those illustrated (see [66]). 2 Note that prasugrel and ticagrelor are only recommended when not contraindicated clinically. Reprinted from [66] by permission of John Wiley and Sons © 2013 American Society for Clinical Pharmacology and Therapeutics.
See this image and copyright information in PMC

References

    1. Sangkuhl K, Shuldiner AR, Klein TE, et al. Platelet aggregation pathway. Pharmacogenetics and genomics. 2011 Aug;21(8):516–21. - PMC - PubMed
    1. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and haemostasis. 2009 Aug;102(2):248–57. - PubMed
    1. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 Jun 19;49(24):2312–7. - PubMed
    1. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013 Dec 17;62(24):2261–73. - PubMed
    1. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):141–52. - PubMed

Publication types

MeSH terms